Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: For the treatment of liver fibrosis, several novel cell therapies have been proposed. Autologous macrophage therapy has been reported as one of the promising treatments. So far, most studies have used colony-stimulating factor 1 (CSF-1) to induce the differentiation of macrophage progenitor cells. The receptor for CSF-1, CSF-1R possesses another ligand, interleukin 34. However, the therapeutic capacity for liver fibrosis by interleukin 34-induced macrophages has not been evaluated. Methods: We have employed acute (bile duct ligation) and chronic (administration of carbon tetrachloride or thioacetamide) liver fibrosis models. Using these models, we evaluated the therapeutic capacity of macrophages induced by interleukin 34-based conditions. In most experiments, interleukin 4 was also added to the differentiation process to induce alternative-activated macrophages. As a mechanism analysis, we have examined liver inflammation and damage, the status of stellate cells, and the immunosuppressive capacity of the macrophages. Human macrophages were differentiated from CD14+ monocytes and analyzed. Results: In both acute and chronic liver damage experiments, interleukin 34-induced macrophages significantly ameliorated liver fibrosis. The addition of interleukin 4 to the differentiation process resulted in an increase of obtained macrophages and a bias to alternative activated macrophages (so-called M2). The alternative activated macrophages (M2-type) showed a reproducible therapeutic effect of liver fibrosis with a suppression of parameters of liver inflammation and damage, stellate cells, and T cell activation. Similar macrophages could be differentiated from human CD14+ monocytes in the presence of interleukin 34 plus interleukin 4, and a therapeutic effect was observed using a humanized mouse model. Conclusions: Interleukin 34-induced macrophages, particularly when additionally stimulated with interleukin 4, significantly ameliorated the liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, in liver fibrosis mouse models, infusion of bone marrow-derived macrophages (BMDMs) or macrophages induced by IL-34-conditioned culture mitigated fibrosis by increasing collagen degradation and inducing HSC apoptosis, among other mechanisms (72, 73).”
From Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics (2026) · cites this paper as [73]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous preclinical studies have shown that macrophage therapy can reduce carbon tetrachloride–induced liver fibrosis (47–50) or promote the repair of acute liver injury repair (44, 51).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Junqueira, L. C. U., Bignolas, G., & Brentani, R. R. (1979) · The Histochemical Journal · doi:10.1007/bf01002772 · Cited by 2,574
Klinge, U., Park, J.-K., & Klosterhalfen, B. (2013) · Pathobiology · doi:10.1159/000348446 · Cited by 1,783
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Wang, Y., Szretter, K. J., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., Barrow, A. D., Diamond, M. S., & Colonna, M. (2012) · Nature Immunology · doi:10.1038/ni.2360 · Cited by 1,011
CSF-1 receptor signaling in myeloid cells.
Stanley, E. R., & Chitu, V. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021857 · Cited by 825
Macrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
Thomas, J. A., Pope, C., Wojtacha, D., Robson, A. J., Gordon-Walker, T. T., Hartland, S., Ramachandran, P., Van Deemter, M., Hume, D. A., Iredale, J. P., et al. (2011) · Hepatology · doi:10.1002/hep.24315 · Cited by 346
Cell therapy for liver disease: From liver transplantation to cell factory
Forbes, S. J., Gupta, S., & Dhawan, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.040 · Cited by 325
Tag, C. G., Sauer-Lehnen, S., Weiskirchen, S., Borkham-Kamphorst, E., Tolba, R. H., Tacke, F., & Weiskirchen, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52438 · Cited by 306
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
Tan, Z., Sun, H., Xue, T., Gan, C., Liu, H., Xie, Y., Yao, Y., & Ye, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730176 · Cited by 215
Huber, S., Hoffmann, R., Muskens, F., & Voehringer, D. (2010) · Blood · doi:10.1182/blood-2010-02-271981 · Cited by 204
Safety profile of autologous macrophage therapy for liver cirrhosis
Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0599-8 · Cited by 202
Baghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Putra, W. E., Endo, D., Watari, H., Sakuragi, N., Hida, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1170 · Cited by 180
Self-citationInterleukin-34, a comprehensive review
Baghdadi, M., Umeyama, Y., Hama, N., Kobayashi, T., Han, N., Wada, H., & Seino, K.-I. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr1117-457r · Cited by 163
Self-citationWatanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Macrophage Phenotype in Liver Injury and Repair
Sun, Y. ‐., Li, X. ‐., Meng, X. ‐., Huang, C., Zhang, L., & Li, J. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12468 · Cited by 137
Regulatory T cells (Tregs) in liver fibrosis
Wu, K.-J., Qian, Q.-F., Zhou, J.-R., Sun, D.-L., Duan, Y.-F., Zhu, X., Sartorius, K., & Lu, Y.-J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01347-8 · Cited by 83
Promising Therapy Candidates for Liver Fibrosis
Wang, P., Koyama, Y., Liu, X., Xu, J., Ma, H.-Y., Liang, S., Kim, I. H., Brenner, D. A., & Kisseleva, T. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00047 · Cited by 81
Interleukin 34, from pathogenesis to clinical applications
Baghdadi, M., Endo, H., Tanaka, Y., Wada, H., & Seino, K. (2017) · Cytokine · doi:10.1016/j.cyto.2017.08.020 · Cited by 81
Self-citationHepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation
Tadokoro, T., Murata, S., Kato, M., Ueno, Y., Tsuchida, T., Okumura, A., Kuse, Y., Konno, T., Uchida, Y., Yamakawa, Y., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg0338 · Cited by 58
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
Hama, N., Kobayashi, T., Han, N., Kitagawa, F., Kajihara, N., Otsuka, R., Wada, H., Lee, H., Rhee, H., Hasegawa, Y., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101584 · Cited by 34
Self-citationInterleukin-34 expression in ovarian cancer: a possible correlation with disease progression
Endo, H., Hama, N., Baghdadi, M., Ishikawa, K., Otsuka, R., Wada, H., Asano, H., Endo, D., Konno, Y., Kato, T., et al. (2019) · International Immunology · doi:10.1093/intimm/dxz074 · Cited by 33
Self-citationKajihara, N., Kobayashi, T., Otsuka, R., Nio‐Kobayashi, J., Oshino, T., Takahashi, M., Imanishi, S., Hashimoto, A., Wada, H., & Seino, K.-I. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03293-3 · Cited by 29
Self-citationBromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells
Han, N., Anwar, D., Hama, N., Kobayashi, T., Suzuki, H., Takahashi, H., Wada, H., Otsuka, R., Baghdadi, M., & Seino, K.-I. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00129-4 · Cited by 9
Self-citationHan, N., Wada, H., Kobayashi, T., Otsuka, R., & Seino, K.-I. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2238499 · Cited by 5
Self-citation
Cited by
Shi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv2106 · Cited by 30
New perspectives in the treatment of liver cirrhosis: targeting macrophage regulatory mechanisms
Zheng, S., Li, S., Wang, Q., Zao, X., Li, X., Qi, W., Cheng, F., Yuexiao, G. E. N. G., Zhang, P., Shi, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07239-y · Cited by 6
“Studies have shown that inducing the polarization of M2-type macrophages helps slow the progression of fibrosis and improves liver function in liver fibrosis models [18, 19].”
Role of IL ‐34 in Tumors and Its Application to Regulate Inflammation
Igarashi, Y., & Seino, K.-I. (2025) · Cancer Science · doi:10.1111/cas.70020 · Cited by 4
Self-citationChen, L., Chen, Y., Zhao, M., Yang, X., Sutte, K., Lu, M., Chen, J., Zheng, X., Yang, D., & Liu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1814879 · Cited by 1
Intestinal reengineering: Scientific advances in intestinal transplantation
Rong, Y., Nie, C.-Y., Zhou, J.-D., Wang, Z., Wu, D. W., Wu, S.-W., & Xie, Z. (2025) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v17.i10.111672 · Cited by 1
“Targeting macrophage polarization is another promising avenue: Colony-stimulating factor-1 receptor inhibitors selectively deplete profibrotic M2 macrophages and attenuate intestinal fibrosis in experimental models[196,197].”
Metadata
- Authors
- Igarashi, Y., Wada, H., Muto, M., Sone, R., Hasegawa, Y., & Seino, K.-I.
- Affiliations
- Hokkaido University (JP)
- Medinet Co., Ltd. (Japan) (JP)
- Kazusa DNA Research Institute (JP)
- Corresponding author
- Seino, Ken-ichiro
- Venue
- Inflammation and Regeneration
- Published
- 2025-01-24
- Volume
- 45
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- PMC
- PMC11758727
- OpenAlex
- W4406807889
- Cited by
- 5
- References
- 30
- Citations by year
- 2026: 1 · 2025: 4
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Inflammation and Regeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- AMED (JP24fk0210117)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver fibrosis, IL-34, IL-4, alternative activated macrophages, M2 macrophages, macrophage differentiation, CD14+ monocytes, hepatic stellate cells, liver inflammation, T cell activation, bile duct ligation, carbon tetrachloride, thioacetamide, humanized mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.